Related Experiment Video
Updated: Jun 24, 2026

Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin
P H A Halkes1, J van Gijn, L J Kappelle
1Department of Neurology, Rudolf Magnus Institute of Neuroscience and Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands. phalkes@umcutrecht.nl
Abstract:
A considerable proportion of patients discontinue dipyridamole therapy because of headache. Risk indicators for the development of dipyridamole induced headache were identified by means of an exploratory analysis of data from the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) and the Second European Stroke Prevention Study (ESPS 2). In ESPRIT, dipyridamole induced headache was significantly associated with female sex, absence of hypertension and non-smoking (area under the receiver operator characteristic (ROC) curve 0.63 (95% CI 0.58 to 0.68)) and in ESPS 2 with female sex and absence of ischaemic lesions on imaging (area under the ROC curve 0.64 (95% CI 0.59 to 0.69)).
Related Concept Videos
Transient Ischemic Attack l: Introduction
Ischemic Stroke l: Introduction
Hemorrhagic Stroke l: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Arteries of the Head and Neck
The internal carotid arteries supply blood to the anterior portion of the cerebrum. They enter the...
Coronary Artery Disease III: Clinical Manifestations
